Global Clonorchiasis Market
Global Clonorchiasis Market

Clonorchiasis Comprehensive Study by Treatment (Praziquantel, Cystic, Biltricide, Others), Parasites (Clonorchis Sinensis, Opisthorchis Viverrini, Opisthorchis Felineus, Others), Diagnosis (Microscopic Examination, X-ray, Serologic Tests, Others), End User (Hospital, Clinics, Others) Players and Region - Global Market Outlook to 2025

Clonorchiasis Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Oct 2020 Edition 216 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Clonorchiasis Market Overview:
Clonorchiasis is a common infection of dogs and other fish-eating carnivores in China, the Democratic People’s Republic of Korea, the Republic of Korea, and Viet Nam. but some patients may have a fever, rash, malaise, and right upper quadrant abdominal discomfort. Chronic infections may be manifested as recurrent pyogenic cholangitis, cholecystitis, obstructive jaundice, hepatomegaly, cholecystitis, multiple hepatic tumors, cholelithiasis, pancreatitis, and cholangiocarcinoma. Clonorchiasis is still highly prevalent among inhabitants in the riverside areas of southern Korea.

Growth Drivers
  • The Increasing Prevalence of Chronic Diseases
  • Increasing Expenditure to Boost the Penetration Rate of Treatments of the Clonorchiasis Diseases

Market Trends
  • The Growing Acceptance of the Vaccines for the Prevention and Control of Clonorchiasis Diseases

Roadblocks
  • Increased Drug Resistance

Opportunities
  • The Rising Initiatives and Programs to Eliminate Clonorchiasis Diseases
  • Increasing Clinical Trial Studies for the Development of New Drugs

Challenges
  • Lack of Effective Therapies


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer (United States), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Abbott (United States). Additionally, following companies can also be profiled that are part of our coverage like Arsanis, Inc. (Austria), Novabiotics (United Kingdom), GlaxoSmithKline plc. (United Kingdom) and Teva Pharmaceutical Industries Ltd (Taiwan). Analyst at AMA Research see European and United States Players to retain maximum share of Global Clonorchiasis market by 2025. Considering Market by Treatment, the sub-segment i.e. Praziquantel will boost the Clonorchiasis market. Considering Market by Parasites, the sub-segment i.e. Clonorchis Sinensis will boost the Clonorchiasis market. Considering Market by Diagnosis, the sub-segment i.e. Microscopic Examination will boost the Clonorchiasis market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Clonorchiasis market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Clonorchiasis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Clonorchiasis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Clonorchiasis Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Treatment
  • Praziquantel
  • Cystic
  • Biltricide
  • Others

By Parasites
  • Clonorchis Sinensis
  • Opisthorchis Viverrini
  • Opisthorchis Felineus
  • Others

By Diagnosis
  • Microscopic Examination
  • X-ray
  • Serologic Tests
  • Others

By End User
  • Hospital
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Prevalence of Chronic Diseases
      • 3.2.2. Increasing Expenditure to Boost the Penetration Rate of Treatments of the Clonorchiasis Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Effective Therapies
    • 3.4. Market Trends
      • 3.4.1. The Growing Acceptance of the Vaccines for the Prevention and Control of Clonorchiasis Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Clonorchiasis, by Treatment, Parasites, Diagnosis, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Clonorchiasis (Value)
      • 5.2.1. Global Clonorchiasis by: Treatment (Value)
        • 5.2.1.1. Praziquantel
        • 5.2.1.2. Cystic
        • 5.2.1.3. Biltricide
        • 5.2.1.4. Others
      • 5.2.2. Global Clonorchiasis by: Parasites (Value)
        • 5.2.2.1. Clonorchis Sinensis
        • 5.2.2.2. Opisthorchis Viverrini
        • 5.2.2.3. Opisthorchis Felineus
        • 5.2.2.4. Others
      • 5.2.3. Global Clonorchiasis by: Diagnosis (Value)
        • 5.2.3.1. Microscopic Examination
        • 5.2.3.2. X-ray
        • 5.2.3.3. Serologic Tests
        • 5.2.3.4. Others
      • 5.2.4. Global Clonorchiasis by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Clonorchiasis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Clonorchiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Provet (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Virbac (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Clonorchiasis Sale, by Treatment, Parasites, Diagnosis, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Clonorchiasis (Value)
      • 7.2.1. Global Clonorchiasis by: Treatment (Value)
        • 7.2.1.1. Praziquantel
        • 7.2.1.2. Cystic
        • 7.2.1.3. Biltricide
        • 7.2.1.4. Others
      • 7.2.2. Global Clonorchiasis by: Parasites (Value)
        • 7.2.2.1. Clonorchis Sinensis
        • 7.2.2.2. Opisthorchis Viverrini
        • 7.2.2.3. Opisthorchis Felineus
        • 7.2.2.4. Others
      • 7.2.3. Global Clonorchiasis by: Diagnosis (Value)
        • 7.2.3.1. Microscopic Examination
        • 7.2.3.2. X-ray
        • 7.2.3.3. Serologic Tests
        • 7.2.3.4. Others
      • 7.2.4. Global Clonorchiasis by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Clonorchiasis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Clonorchiasis: by Treatment(USD Million)
  • Table 2. Clonorchiasis Praziquantel , by Region USD Million (2014-2019)
  • Table 3. Clonorchiasis Cystic , by Region USD Million (2014-2019)
  • Table 4. Clonorchiasis Biltricide , by Region USD Million (2014-2019)
  • Table 5. Clonorchiasis Others , by Region USD Million (2014-2019)
  • Table 6. Clonorchiasis: by Parasites(USD Million)
  • Table 7. Clonorchiasis Clonorchis Sinensis , by Region USD Million (2014-2019)
  • Table 8. Clonorchiasis Opisthorchis Viverrini , by Region USD Million (2014-2019)
  • Table 9. Clonorchiasis Opisthorchis Felineus , by Region USD Million (2014-2019)
  • Table 10. Clonorchiasis Others , by Region USD Million (2014-2019)
  • Table 11. Clonorchiasis: by Diagnosis(USD Million)
  • Table 12. Clonorchiasis Microscopic Examination , by Region USD Million (2014-2019)
  • Table 13. Clonorchiasis X-ray , by Region USD Million (2014-2019)
  • Table 14. Clonorchiasis Serologic Tests , by Region USD Million (2014-2019)
  • Table 15. Clonorchiasis Others , by Region USD Million (2014-2019)
  • Table 16. Clonorchiasis: by End User(USD Million)
  • Table 17. Clonorchiasis Hospital , by Region USD Million (2014-2019)
  • Table 18. Clonorchiasis Clinics , by Region USD Million (2014-2019)
  • Table 19. Clonorchiasis Others , by Region USD Million (2014-2019)
  • Table 20. South America Clonorchiasis, by Country USD Million (2014-2019)
  • Table 21. South America Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 22. South America Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 23. South America Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 24. South America Clonorchiasis, by End User USD Million (2014-2019)
  • Table 25. Brazil Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 26. Brazil Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 27. Brazil Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 28. Brazil Clonorchiasis, by End User USD Million (2014-2019)
  • Table 29. Argentina Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 30. Argentina Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 31. Argentina Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 32. Argentina Clonorchiasis, by End User USD Million (2014-2019)
  • Table 33. Rest of South America Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 34. Rest of South America Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 35. Rest of South America Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 36. Rest of South America Clonorchiasis, by End User USD Million (2014-2019)
  • Table 37. Asia Pacific Clonorchiasis, by Country USD Million (2014-2019)
  • Table 38. Asia Pacific Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 39. Asia Pacific Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 40. Asia Pacific Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 41. Asia Pacific Clonorchiasis, by End User USD Million (2014-2019)
  • Table 42. China Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 43. China Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 44. China Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 45. China Clonorchiasis, by End User USD Million (2014-2019)
  • Table 46. Japan Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 47. Japan Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 48. Japan Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 49. Japan Clonorchiasis, by End User USD Million (2014-2019)
  • Table 50. India Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 51. India Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 52. India Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 53. India Clonorchiasis, by End User USD Million (2014-2019)
  • Table 54. South Korea Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 55. South Korea Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 56. South Korea Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 57. South Korea Clonorchiasis, by End User USD Million (2014-2019)
  • Table 58. Taiwan Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 59. Taiwan Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 60. Taiwan Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 61. Taiwan Clonorchiasis, by End User USD Million (2014-2019)
  • Table 62. Australia Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 63. Australia Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 64. Australia Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 65. Australia Clonorchiasis, by End User USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Clonorchiasis, by End User USD Million (2014-2019)
  • Table 70. Europe Clonorchiasis, by Country USD Million (2014-2019)
  • Table 71. Europe Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 72. Europe Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 73. Europe Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 74. Europe Clonorchiasis, by End User USD Million (2014-2019)
  • Table 75. Germany Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 76. Germany Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 77. Germany Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 78. Germany Clonorchiasis, by End User USD Million (2014-2019)
  • Table 79. France Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 80. France Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 81. France Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 82. France Clonorchiasis, by End User USD Million (2014-2019)
  • Table 83. Italy Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 84. Italy Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 85. Italy Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 86. Italy Clonorchiasis, by End User USD Million (2014-2019)
  • Table 87. United Kingdom Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 88. United Kingdom Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 89. United Kingdom Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 90. United Kingdom Clonorchiasis, by End User USD Million (2014-2019)
  • Table 91. Netherlands Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 92. Netherlands Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 93. Netherlands Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 94. Netherlands Clonorchiasis, by End User USD Million (2014-2019)
  • Table 95. Rest of Europe Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 96. Rest of Europe Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 97. Rest of Europe Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 98. Rest of Europe Clonorchiasis, by End User USD Million (2014-2019)
  • Table 99. MEA Clonorchiasis, by Country USD Million (2014-2019)
  • Table 100. MEA Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 101. MEA Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 102. MEA Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 103. MEA Clonorchiasis, by End User USD Million (2014-2019)
  • Table 104. Middle East Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 105. Middle East Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 106. Middle East Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 107. Middle East Clonorchiasis, by End User USD Million (2014-2019)
  • Table 108. Africa Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 109. Africa Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 110. Africa Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 111. Africa Clonorchiasis, by End User USD Million (2014-2019)
  • Table 112. North America Clonorchiasis, by Country USD Million (2014-2019)
  • Table 113. North America Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 114. North America Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 115. North America Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 116. North America Clonorchiasis, by End User USD Million (2014-2019)
  • Table 117. United States Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 118. United States Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 119. United States Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 120. United States Clonorchiasis, by End User USD Million (2014-2019)
  • Table 121. Canada Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 122. Canada Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 123. Canada Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 124. Canada Clonorchiasis, by End User USD Million (2014-2019)
  • Table 125. Mexico Clonorchiasis, by Treatment USD Million (2014-2019)
  • Table 126. Mexico Clonorchiasis, by Parasites USD Million (2014-2019)
  • Table 127. Mexico Clonorchiasis, by Diagnosis USD Million (2014-2019)
  • Table 128. Mexico Clonorchiasis, by End User USD Million (2014-2019)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Clonorchiasis: by Treatment(USD Million)
  • Table 140. Clonorchiasis Praziquantel , by Region USD Million (2020-2025)
  • Table 141. Clonorchiasis Cystic , by Region USD Million (2020-2025)
  • Table 142. Clonorchiasis Biltricide , by Region USD Million (2020-2025)
  • Table 143. Clonorchiasis Others , by Region USD Million (2020-2025)
  • Table 144. Clonorchiasis: by Parasites(USD Million)
  • Table 145. Clonorchiasis Clonorchis Sinensis , by Region USD Million (2020-2025)
  • Table 146. Clonorchiasis Opisthorchis Viverrini , by Region USD Million (2020-2025)
  • Table 147. Clonorchiasis Opisthorchis Felineus , by Region USD Million (2020-2025)
  • Table 148. Clonorchiasis Others , by Region USD Million (2020-2025)
  • Table 149. Clonorchiasis: by Diagnosis(USD Million)
  • Table 150. Clonorchiasis Microscopic Examination , by Region USD Million (2020-2025)
  • Table 151. Clonorchiasis X-ray , by Region USD Million (2020-2025)
  • Table 152. Clonorchiasis Serologic Tests , by Region USD Million (2020-2025)
  • Table 153. Clonorchiasis Others , by Region USD Million (2020-2025)
  • Table 154. Clonorchiasis: by End User(USD Million)
  • Table 155. Clonorchiasis Hospital , by Region USD Million (2020-2025)
  • Table 156. Clonorchiasis Clinics , by Region USD Million (2020-2025)
  • Table 157. Clonorchiasis Others , by Region USD Million (2020-2025)
  • Table 158. South America Clonorchiasis, by Country USD Million (2020-2025)
  • Table 159. South America Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 160. South America Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 161. South America Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 162. South America Clonorchiasis, by End User USD Million (2020-2025)
  • Table 163. Brazil Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 164. Brazil Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 165. Brazil Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 166. Brazil Clonorchiasis, by End User USD Million (2020-2025)
  • Table 167. Argentina Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 168. Argentina Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 169. Argentina Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 170. Argentina Clonorchiasis, by End User USD Million (2020-2025)
  • Table 171. Rest of South America Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 172. Rest of South America Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 173. Rest of South America Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 174. Rest of South America Clonorchiasis, by End User USD Million (2020-2025)
  • Table 175. Asia Pacific Clonorchiasis, by Country USD Million (2020-2025)
  • Table 176. Asia Pacific Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 177. Asia Pacific Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 178. Asia Pacific Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 179. Asia Pacific Clonorchiasis, by End User USD Million (2020-2025)
  • Table 180. China Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 181. China Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 182. China Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 183. China Clonorchiasis, by End User USD Million (2020-2025)
  • Table 184. Japan Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 185. Japan Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 186. Japan Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 187. Japan Clonorchiasis, by End User USD Million (2020-2025)
  • Table 188. India Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 189. India Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 190. India Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 191. India Clonorchiasis, by End User USD Million (2020-2025)
  • Table 192. South Korea Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 193. South Korea Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 194. South Korea Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 195. South Korea Clonorchiasis, by End User USD Million (2020-2025)
  • Table 196. Taiwan Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 197. Taiwan Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 198. Taiwan Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 199. Taiwan Clonorchiasis, by End User USD Million (2020-2025)
  • Table 200. Australia Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 201. Australia Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 202. Australia Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 203. Australia Clonorchiasis, by End User USD Million (2020-2025)
  • Table 204. Rest of Asia-Pacific Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 205. Rest of Asia-Pacific Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 206. Rest of Asia-Pacific Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 207. Rest of Asia-Pacific Clonorchiasis, by End User USD Million (2020-2025)
  • Table 208. Europe Clonorchiasis, by Country USD Million (2020-2025)
  • Table 209. Europe Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 210. Europe Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 211. Europe Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 212. Europe Clonorchiasis, by End User USD Million (2020-2025)
  • Table 213. Germany Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 214. Germany Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 215. Germany Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 216. Germany Clonorchiasis, by End User USD Million (2020-2025)
  • Table 217. France Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 218. France Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 219. France Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 220. France Clonorchiasis, by End User USD Million (2020-2025)
  • Table 221. Italy Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 222. Italy Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 223. Italy Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 224. Italy Clonorchiasis, by End User USD Million (2020-2025)
  • Table 225. United Kingdom Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 226. United Kingdom Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 227. United Kingdom Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 228. United Kingdom Clonorchiasis, by End User USD Million (2020-2025)
  • Table 229. Netherlands Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 230. Netherlands Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 231. Netherlands Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 232. Netherlands Clonorchiasis, by End User USD Million (2020-2025)
  • Table 233. Rest of Europe Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 234. Rest of Europe Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 235. Rest of Europe Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 236. Rest of Europe Clonorchiasis, by End User USD Million (2020-2025)
  • Table 237. MEA Clonorchiasis, by Country USD Million (2020-2025)
  • Table 238. MEA Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 239. MEA Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 240. MEA Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 241. MEA Clonorchiasis, by End User USD Million (2020-2025)
  • Table 242. Middle East Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 243. Middle East Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 244. Middle East Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 245. Middle East Clonorchiasis, by End User USD Million (2020-2025)
  • Table 246. Africa Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 247. Africa Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 248. Africa Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 249. Africa Clonorchiasis, by End User USD Million (2020-2025)
  • Table 250. North America Clonorchiasis, by Country USD Million (2020-2025)
  • Table 251. North America Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 252. North America Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 253. North America Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 254. North America Clonorchiasis, by End User USD Million (2020-2025)
  • Table 255. United States Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 256. United States Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 257. United States Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 258. United States Clonorchiasis, by End User USD Million (2020-2025)
  • Table 259. Canada Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 260. Canada Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 261. Canada Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 262. Canada Clonorchiasis, by End User USD Million (2020-2025)
  • Table 263. Mexico Clonorchiasis, by Treatment USD Million (2020-2025)
  • Table 264. Mexico Clonorchiasis, by Parasites USD Million (2020-2025)
  • Table 265. Mexico Clonorchiasis, by Diagnosis USD Million (2020-2025)
  • Table 266. Mexico Clonorchiasis, by End User USD Million (2020-2025)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Clonorchiasis: by Treatment USD Million (2014-2019)
  • Figure 5. Global Clonorchiasis: by Parasites USD Million (2014-2019)
  • Figure 6. Global Clonorchiasis: by Diagnosis USD Million (2014-2019)
  • Figure 7. Global Clonorchiasis: by End User USD Million (2014-2019)
  • Figure 8. South America Clonorchiasis Share (%), by Country
  • Figure 9. Asia Pacific Clonorchiasis Share (%), by Country
  • Figure 10. Europe Clonorchiasis Share (%), by Country
  • Figure 11. MEA Clonorchiasis Share (%), by Country
  • Figure 12. North America Clonorchiasis Share (%), by Country
  • Figure 13. Global Clonorchiasis share by Players 2019 (%)
  • Figure 14. Global Clonorchiasis share by Players (Top 3) 2019(%)
  • Figure 15. Global Clonorchiasis share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2019
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 21. Provet (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Provet (Switzerland) Revenue: by Geography 2019
  • Figure 23. Virbac (India) Revenue, Net Income and Gross profit
  • Figure 24. Virbac (India) Revenue: by Geography 2019
  • Figure 25. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 26. Cipla (India) Revenue: by Geography 2019
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 29. CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India) Revenue: by Geography 2019
  • Figure 31. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 35. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott (United States) Revenue: by Geography 2019
  • Figure 37. Global Clonorchiasis: by Treatment USD Million (2020-2025)
  • Figure 38. Global Clonorchiasis: by Parasites USD Million (2020-2025)
  • Figure 39. Global Clonorchiasis: by Diagnosis USD Million (2020-2025)
  • Figure 40. Global Clonorchiasis: by End User USD Million (2020-2025)
  • Figure 41. South America Clonorchiasis Share (%), by Country
  • Figure 42. Asia Pacific Clonorchiasis Share (%), by Country
  • Figure 43. Europe Clonorchiasis Share (%), by Country
  • Figure 44. MEA Clonorchiasis Share (%), by Country
  • Figure 45. North America Clonorchiasis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Bayer AG (Germany)
  • Provet (Switzerland)
  • Virbac (India)
  • Cipla (India)
  • Novartis AG (Switzerland)
  • CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India)
  • Merck & Co., Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Abbott (United States)
Additional players considered in the study are as follows:
Arsanis, Inc. (Austria) , Novabiotics (United Kingdom) , GlaxoSmithKline plc. (United Kingdom) , Teva Pharmaceutical Industries Ltd (Taiwan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation